CommercialPrior AuthLow impact
08.01.52g, Mogamulizumab-kpkc (Poteligeo®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
Medical necessity criteria for Mogamulizumab-kpkc (Poteligeo®) have been updated for commercial insurance plans. This affects billing and prior authorization requirements for this specialty oncology medication used to treat certain T-cell lymphomas.
Action Required
By July 1, 2025: Billing team and providers must review updated medical necessity criteria for Mogamulizumab-kpkc (Poteligeo®) prescriptions. Update prior authorization workflows to align with new criteria. Ensure documentation meets revised medical necessity requirements to prevent claim denials.